Investor Relations

Press Releases

June 30, 2025

Press release: Availability of the Q2 2025 Aide mémoire

June 30, 2025

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Read the Press Release

June 25, 2025

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Read the Press Release

See more press releases

Upcoming Events

19Jun

2025

JPM European Healthcare Forum

08:00 - 15:00 GMT (London)

Conferences

31Jul

2025

Second Quarter 2025

Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EDT)

Quarterly results

Discover more

24Oct

2025

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results

All our events

Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing

Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

30th Consecutive Year of Dividend Increase

Learn more

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.